-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Uo5AlQhAij6287H/TkCR6Um8uY317UvZv9ds4EQP9dNK1RnLX4xZQ17YmRzo/Lku 393SmW+JcsP4u5EE7bzpxw== 0000912057-02-024912.txt : 20020621 0000912057-02-024912.hdr.sgml : 20020621 20020621100312 ACCESSION NUMBER: 0000912057-02-024912 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020621 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD STREET 2: D-322 AP6D CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 8479376100 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SANGSTAT MEDICAL CORP CENTRAL INDEX KEY: 0000913610 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943076069 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-44874 FILM NUMBER: 02683861 BUSINESS ADDRESS: STREET 1: 6300 DUMBARTON CIRCLE CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 5107894300 MAIL ADDRESS: STREET 1: 6300 DUMBARTON CIRCLE CITY: FREMONT STATE: CA ZIP: 94555 SC 13D/A 1 a2082761zsc13da.htm SC 13D/A
QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*

SangStat Medical Corporation
(Name of Issuer)

Common Stock, par value $0.001 per share
(Title of Class of Securities)

801003104
(CUSIP Number)

Jose M. de Lasa, 100 Abbott Park Road
Abbott Park, Illinois 60064-6049; Phone 847 937 8905
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

June 14, 2002
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.    801003104        
             
1)   NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Abbott Laboratories
IRS Identification No.: 36-0698440

 
 
 
 
 
 
 
2)   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP        
        (a)   o
        (b)   o

 
 
 
 
 
 
 
3)   SEC USE ONLY        

 
 
 
 
 
 
 
4)   SOURCE OF FUNDS        

 
 
Not Applicable
 
 
5)   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
            o

 
 
 
 
 
 
 
6)   CITIZENSHIP OR PLACE OF ORGANIZATION

 
 
Illinois
 
 
NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		   (7)   SOLE VOTING POWER
220,000

 
 
 
 
 
 
 
       
        (8)   SHARED VOTING POWER
0

 
 
 
 
 
 
 
       
        (9)   SOLE DISPOSITIVE POWER
220,000

 
 
 
 
 
 
 
       
        (10)   SHARED DISPOSITIVE POWER
0

 
 
 
 
 
 
 
11)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 
 
220,000
 
 
 
 
12)   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
            o

 
 
 
 
 
 
 
13)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 
 
0.8% (see Item 5 below)
 
 
 
 
14)   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 
 
CO
 
 
 
 

Page 2 of 4 pages

The following information amends and supplements the original Schedule 13D filed by Abbott Laboratories ("Abbott") on August 16, 1999.


Item 1. Security and Issuer

        This statement relates to shares of the common stock, par value $0.001 per share (the "Common Stock"), of SangStat Medical Corporation, a Delaware corporation (the "Issuer"), whose principal executive offices are located at 6300 Dumbarton Circle, Fremont, California 94555.


Item 5. Interest in Securities of the Issuer

        (a) As of June 18, 2002, Abbott was the beneficial owner of 220,000 shares of Common Stock (the "Shares"), representing approximately 0.8% of the outstanding shares of the Common Stock. The calculation of the foregoing percentage is based on the number of shares of Common Stock shown as being outstanding on the Form 10-Q Quarterly Report filed by the Issuer with the Securities and Exchange Commission ("SEC") for the quarterly period ended March 31, 2002.

        (b) Abbott has sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of the Shares.

        (c) In the past 60 days, Abbott has effected the following open market sales of the Common Stock:

Date
   Number of Shares Sold
   Average Price Per Share
June 10, 2002   75,000     $20.8500
June 11, 2002   78,996     $20.4117
June 13, 2002   75,000     $19.6700
June 14, 2002   100,000   $19.6645
June 17, 2002   125,000   $20.5532
June 18, 2002   220,000   $20.7500

        (e) Based on Abbott's review of the Issuer's Form 10-Q Quarterly Reports and Form 10-K Annual Reports filed with the SEC, Abbott ceased to be the beneficial owner of more than five percent of the Common Stock no later than March 21, 2000 due to increases in the outstanding shares of the Common Stock.

Page 3 of 4 pages


Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Abbott Laboratories

DATED: June 20, 2002
 
By:
 
/s/  THOMAS C. FREYMAN      
Thomas C. Freyman, Senior Vice President,
Finance and Chief Financial Officer

Page 4 of 4 Pages



QuickLinks

 -----END PRIVACY-ENHANCED MESSAGE-----